Eylea 40 mg/mL solution for injection in pre-filled syringe clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
TELeMAC - Comparative multicenter randomized study of aflibercept versus placebo in macular telangiectasia type 1
This study looks at how well a medicine called aflibercept (Eylea) works compared to a dummy treatment for a rare eye condition called macular telangiectasia type 1. Researchers want to see if it can improve swelling at the back of the eye and help sight.
For: macular telangiectasia type 1France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study is testing a new treatment called OPT-302, given alongside an existing treatment (Eylea), for a serious eye condition called 'wet' Age-related Macular Degeneration (AMD). Doctors want to see if combining these treatments helps people see better than Eylea alone.
For: Neovascular Age-related Macular Degeneration (wet AMD)Czechia · Bulgaria · Croatia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Neovascular glaucoma prevention by intravitreal injections of anti-VEGF in patients treated by protontherapy in case of large choroid melanoma
This study looks at preventing a serious eye condition called neovascular glaucoma, which can happen after proton therapy for a large choroid melanoma. Researchers are using a drug called Eylea to see if it can help stop this condition from developing in patients who've had this specific treatment.
For: Patient with large choroid melanoma 7 mm thick and/or more than 15 mm of basal diameter treated by proton therapyFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Spontaneous Retinal Arterial Pulsations (SRAPs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVOs) in patients treated or not with intravitreal injections of aflibercept
This study looks at a tiny pulse in the eye's blood vessels to see if it can predict how well people with a common eye condition, central retinal vein occlusion (CRVO), respond to a specific eye injection treatment. It checks how much their eyesight improves.
For: central retinal vein occlusionsFrance - Ongoing, recruitingPhase III and phase IV (Integrated)
Faricimab for high-frequent Aflibercept treated Neovascular age-related macular degeneration: a monocenter, randomized, double-masked comparator-controlled study (FAN study)
This study compares two treatments, Vabysmo and Eylea, for a serious eye condition called 'wet' age-related macular degeneration (AMD). The aim is to see which treatment can keep the eye healthy and vision stable for longer, with fewer injections.
For: Neovascular age-related macular degenerationAustria